Protez Pharmaceuticals' Acquisition

Protez Pharmaceuticals was acquired by Novartis on July 21, 2008.

Protez Pharmaceuticals entered a 20-site Phase II human clinical trial in 2008 with its lead compound, PZ-601, a antibiotic candidate focused on drug resistance in difficult to treat infections.…

Articles about Protez Pharmaceuticals' Acquisition: